Next Article in Journal
Regulation of the Expression of DAPK1 by SUMO Pathway
Next Article in Special Issue
The Contribution of the 20S Proteasome to Proteostasis
Previous Article in Journal
Mining for Oxysterols in Cyp7b1−/− Mouse Brain and Plasma: Relevance to Spastic Paraplegia Type 5
Open AccessReview

Intracellular Peptides in Cell Biology and Pharmacology

1
Special Laboratory of Cell Cycle, Center of Toxins, Immune Response and Cell Signaling—CeTICS, Butantan Institute, São Paulo SP 05503-900, Brazil
2
Proteimax Biotecnologia LTDA, São Paulo SP 05581-001, Brazil
3
Remer Consultores Ltda., São Paulo SP 01411-001, Brazil
4
Department of Biochemistry, Chemistry Institute, University of São Paulo 1111, São Paulo 05508-000, Brazil
5
Department of Cell and Developmental Biology, University of São Paulo (USP), São Paulo 05508-000, Brazil
6
Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo (USP), São Paulo 05508-000, Brazil
*
Author to whom correspondence should be addressed.
Biomolecules 2019, 9(4), 150; https://doi.org/10.3390/biom9040150
Received: 28 February 2019 / Revised: 2 April 2019 / Accepted: 12 April 2019 / Published: 16 April 2019
(This article belongs to the Special Issue The Broader Cellular Impact of Proteasome-CSN-eIf3 (PCI) Complexes)
Intracellular peptides are produced by proteasomes following degradation of nuclear, cytosolic, and mitochondrial proteins, and can be further processed by additional peptidases generating a larger pool of peptides within cells. Thousands of intracellular peptides have been sequenced in plants, yeast, zebrafish, rodents, and in human cells and tissues. Relative levels of intracellular peptides undergo changes in human diseases and also when cells are stimulated, corroborating their biological function. However, only a few intracellular peptides have been pharmacologically characterized and their biological significance and mechanism of action remains elusive. Here, some historical and general aspects on intracellular peptides’ biology and pharmacology are presented. Hemopressin and Pep19 are examples of intracellular peptides pharmacologically characterized as inverse agonists to cannabinoid type 1 G-protein coupled receptors (CB1R), and hemopressin fragment NFKF is shown herein to attenuate the symptoms of pilocarpine-induced epileptic seizures. Intracellular peptides EL28 (derived from proteasome 26S protease regulatory subunit 4; Rpt2), PepH (derived from Histone H2B type 1-H), and Pep5 (derived from G1/S-specific cyclin D2) are examples of peptides that function intracellularly. Intracellular peptides are suggested as biological functional molecules, and are also promising prototypes for new drug development. View Full-Text
Keywords: intracellular peptides; proteasome; epilepsy; endocannabinoid; cancer; drug discovery; obesity; insulin resistance intracellular peptides; proteasome; epilepsy; endocannabinoid; cancer; drug discovery; obesity; insulin resistance
Show Figures

Figure 1

MDPI and ACS Style

de Araujo, C.B.; Heimann, A.S.; Remer, R.A.; Russo, L.C.; Colquhoun, A.; Forti, F.L.; Ferro, E.S. Intracellular Peptides in Cell Biology and Pharmacology. Biomolecules 2019, 9, 150.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop